Degrading Mutant KRAS Protein Induces Greater Lung Cancer Regression
5 Articles
5 Articles
A study by the Instituto de Investigación Biomédica (IRB Barcelona) and the Centro de Investigación de Cáncer de Salamanca has revealed that degrading the KRAS protein induces a tumor "marked regression" in preclinical mouse models with lung adenocarcinoma.Read more]]>
A study by the Instituto de Investigación Biomédica (IRB Barcelona) and the Centro de Investigación de Cáncer de Salamanca has revealed that degrading the protein KRAS induces a tumor "marked regression" in preclinical mouse models with lung adenocarcinoma. This strategy, published in the journal Cancer Research, differs from other therapeutic approaches because it is not limited to blocking the activity of the protein, but to degrading it by mo…
However, these treatments often lose effectiveness over time due to the appearance of resistances. Now, a new study explores a different pharmacological strategy based on causing the tumor cells themselves to degrade KRAS. The study, led by IRB Barcelona and the Cancer Research Center (CSIC, USAL, FICUS), shows that destroying mutated KRAS protein, rather than merely blocking its activity, causes a greater regression of lung cancer in preclinica…
Targeting KRAS Degradation Triggers Swift Lung Cancer Regression in
In a groundbreaking advance that reshapes the landscape of lung cancer treatment, researchers from IRB Barcelona and the Centro de Investigación del Cáncer have unveiled a novel pharmacological approach targeting mutant KRAS proteins. KRAS mutations, particularly the KRAS^G12V variant, are infamous drivers in approximately one-third of lung adenocarcinomas, historically rendering cancer cells exceptionally difficult to target therapeutically. Wh…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
